There is no cure for MS, but disease-modifying drugs (DMDs), including the well-established injectable therapies interferon beta (IFNβ) and glatiramer acetate (GA), can delay disease progression if administered with strict adherence to the prescribed dose and administration schedule (2, 3). This evidence concerns the gene IFNB1 and myeloid sarcoma.